OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection

M. R. Leone, S. R. Alexander, John Barry, K. Henell, M. B. Funnell, G. Goldstein, Douglas Norman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Twelve pediatric patients, aged 28 months to 17 years, received OKT3 to reverse renal allograft rejection. In 11 patients, the rejection crisis was resistant to conventional antirejection therapy with high doses of prednisone or polyclonal antithymocyte globulin. Reversal of rejection was successful in 10 patients who completed a treatment course. Because of recurring resistant rejection, five patients received a second course of OKT3, which was successful in reversing the rejection crisis in two. Among these patients, the persistence or the appearance of high levels of circulating T3 lymphocytes after initiating the second treatment course correlated with treatment failure. The immediate side effects associated with OKT3 therapy were translent and medically manageable. We conclude that this monoclonal antibody preparation is a safe and effective treatment for pediatric renal allograft in recipients experiencing rejection crisis resistant to conventional therapy. However, the potential impact of this immunosuppressive medication on long-term renal allograft survival in this patient population remains to be determined.

Original languageEnglish (US)
Pages (from-to)45-50
Number of pages6
JournalThe Journal of Pediatrics
Volume111
Issue number1
DOIs
StatePublished - 1987

Fingerprint

Muromonab-CD3
Allografts
Pediatrics
Kidney
Therapeutics
Antilymphocyte Serum
Immunosuppressive Agents
Prednisone
Treatment Failure
Immunosuppression
Transplant Recipients
Monoclonal Antibodies
Lymphocytes
Population

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection. / Leone, M. R.; Alexander, S. R.; Barry, John; Henell, K.; Funnell, M. B.; Goldstein, G.; Norman, Douglas.

In: The Journal of Pediatrics, Vol. 111, No. 1, 1987, p. 45-50.

Research output: Contribution to journalArticle

Leone, M. R. ; Alexander, S. R. ; Barry, John ; Henell, K. ; Funnell, M. B. ; Goldstein, G. ; Norman, Douglas. / OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection. In: The Journal of Pediatrics. 1987 ; Vol. 111, No. 1. pp. 45-50.
@article{fabf7c9a6c954588b336e9446b8a8f56,
title = "OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection",
abstract = "Twelve pediatric patients, aged 28 months to 17 years, received OKT3 to reverse renal allograft rejection. In 11 patients, the rejection crisis was resistant to conventional antirejection therapy with high doses of prednisone or polyclonal antithymocyte globulin. Reversal of rejection was successful in 10 patients who completed a treatment course. Because of recurring resistant rejection, five patients received a second course of OKT3, which was successful in reversing the rejection crisis in two. Among these patients, the persistence or the appearance of high levels of circulating T3 lymphocytes after initiating the second treatment course correlated with treatment failure. The immediate side effects associated with OKT3 therapy were translent and medically manageable. We conclude that this monoclonal antibody preparation is a safe and effective treatment for pediatric renal allograft in recipients experiencing rejection crisis resistant to conventional therapy. However, the potential impact of this immunosuppressive medication on long-term renal allograft survival in this patient population remains to be determined.",
author = "Leone, {M. R.} and Alexander, {S. R.} and John Barry and K. Henell and Funnell, {M. B.} and G. Goldstein and Douglas Norman",
year = "1987",
doi = "10.1016/S0022-3476(87)80340-2",
language = "English (US)",
volume = "111",
pages = "45--50",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection

AU - Leone, M. R.

AU - Alexander, S. R.

AU - Barry, John

AU - Henell, K.

AU - Funnell, M. B.

AU - Goldstein, G.

AU - Norman, Douglas

PY - 1987

Y1 - 1987

N2 - Twelve pediatric patients, aged 28 months to 17 years, received OKT3 to reverse renal allograft rejection. In 11 patients, the rejection crisis was resistant to conventional antirejection therapy with high doses of prednisone or polyclonal antithymocyte globulin. Reversal of rejection was successful in 10 patients who completed a treatment course. Because of recurring resistant rejection, five patients received a second course of OKT3, which was successful in reversing the rejection crisis in two. Among these patients, the persistence or the appearance of high levels of circulating T3 lymphocytes after initiating the second treatment course correlated with treatment failure. The immediate side effects associated with OKT3 therapy were translent and medically manageable. We conclude that this monoclonal antibody preparation is a safe and effective treatment for pediatric renal allograft in recipients experiencing rejection crisis resistant to conventional therapy. However, the potential impact of this immunosuppressive medication on long-term renal allograft survival in this patient population remains to be determined.

AB - Twelve pediatric patients, aged 28 months to 17 years, received OKT3 to reverse renal allograft rejection. In 11 patients, the rejection crisis was resistant to conventional antirejection therapy with high doses of prednisone or polyclonal antithymocyte globulin. Reversal of rejection was successful in 10 patients who completed a treatment course. Because of recurring resistant rejection, five patients received a second course of OKT3, which was successful in reversing the rejection crisis in two. Among these patients, the persistence or the appearance of high levels of circulating T3 lymphocytes after initiating the second treatment course correlated with treatment failure. The immediate side effects associated with OKT3 therapy were translent and medically manageable. We conclude that this monoclonal antibody preparation is a safe and effective treatment for pediatric renal allograft in recipients experiencing rejection crisis resistant to conventional therapy. However, the potential impact of this immunosuppressive medication on long-term renal allograft survival in this patient population remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0023202343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023202343&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(87)80340-2

DO - 10.1016/S0022-3476(87)80340-2

M3 - Article

VL - 111

SP - 45

EP - 50

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -